are released through compound exocytosis, where granules fuse with each other to form intracellular networks after which α-granule content release is potentiated. 13, 14 Here we propose that GLUT3 translocation to the plasma membrane in the initial single exocytosis phase fuels glucose uptake that generates the energy required for potentiation of exocytosis.
Additionally, platelet degranulation in conjunction with GLUT3 translocation to the plasma membrane may continue to provide glucose for other phenomena, such as clot retraction and microparticle formation. Therefore, it is imperative to better understand the spectrum of mechanisms regulating platelet function that are mediated by the activation-induced increase in glucose metabolism.
Currently, the only functional studies of postactivation glucose metabolism suggest (in vitro) that glucose in the media is required for clot retraction, 15 and inhibiting platelet mitochondrial respiration and glycolysis blocks platelet aggregation. 16 Even less is known about the consequence of metabolism on platelet function in vivo, except for observations showing that systemic administration of glucose increases platelet activation. 17, 18 However, it is unclear whether these effects are directly attributed to platelet metabolism or might result from systemic effects.
To understand the contribution of glucose metabolism to platelet function, we generated a platelet-specific knockout of GLUT3 (GLUT3-KO). This model allowed us to determine the mechanisms by which glucose metabolism regulates activation and postactivation platelet function in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Deletion of GLUT3 Reduces Glucose Metabolism in Platelets
To evaluate the contribution of glucose metabolism to platelet function, we generated GLUT3-KO specifically in platelets. GLUT3-KO was verified via Western blot analysis of platelet lysates ( Figure 1A ). In addition, no compensatory increase in GLUT1 protein was observed. Basal total cellular glucose uptake was reduced by 23% in GLUT3-KO platelets relative to littermate controls ( Figure 1B ). Similar to human platelets, 12, 19 thrombin elicited an increase in glucose uptake in control platelets; however, this effect was abolished in GLUT3-KO platelets ( Figure 1B ). These data are consistent with the proposed model that translocation of GLUT3 to the plasma membrane facilitates postactivation glucose uptake. 12 Although glucose uptake was decreased in GLUT3-KO platelets, both basal and thrombin-mediated glycolysis rates were unchanged ( Figure 1C ). However, after administration of mitochondrial inhibitors, GLUT3-KO platelets failed to increase glycolysis to the same extent as observed in control platelets. These data suggest that resting GLUT3-KO platelets under physiological conditions may sustain glycolysis via GLUT3-independent mechanisms, such as increased glycogenolysis.
Metabolomics profiling of freshly isolated, quiescent platelets revealed that the pentose phosphate pathway and glycolysis were modestly impacted by deletion of GLUT3. However, polyol pathway intermediates fructose and sorbitol were significantly reduced ( Figure 1D ). Importantly, glycogen content was decreased ≈3-fold in GLUT3-KO platelets ( Figure 1D ).
GLUT3 Facilitates Platelet α-Granule Glycolysis
GLUT3 is a bidirectional glucose transporter, which transports glucose by facilitated diffusion. Interestingly, ≈85% of GLUT3 resides in α-granule membranes, and the remaining 15% is located in the plasma membrane under nonstimulated conditions. 12 Because GLUT3 translocates to the plasma membrane after degranulation and degranulation is a terminal process, we considered the possibility that α-granule GLUT3 may play a role in metabolism prior to degranulation. Proteomic analysis of α-granules, where GLUT3 was used as a specific marker of α-granules and proteomic analysis of platelet releasates, indicate that all proteins required for glycolysis are present in these organelles. [20] [21] [22] To support these observations, we measured the activities of hexokinase and LDH (lactate dehydrogenase) in α-granule-enriched subcellular fractions (Figure IA through I I in the online-only Data Supplement). Hexokinase activity was greatest in α-granule-enriched pellets. LDH activity was also detected in α-granule pellets but was also present in other subcellular fractions. α-Granule-enriched fractions also contained mitochondria as evidenced by VDAC (voltage-dependent anion channel) immunoreactivity, and hexokinase can be associated with mitochondria ( Figure IG in the online-only Data Supplement). However, we performed additional centrifugations to separate mitochondria from other membranes. Interestingly, the mitochondrial-enriched fraction contained significant GLUT3 contamination, suggesting close associations between mitochondria and α-granules. Importantly, fractions enriched for GLUT3 that were devoid of mitochondrial markers retained significant hexokinase activity (Figure IH through I I in the online-only Data Supplement) To test the hypothesis that GLUT3 mediates glucose uptake into α-granules from cytosol, for intragranular glycolysis, under basal conditions, we used saponin permeabilization to estimate intragranular glycolysis. After treatment of platelets with 10 ng/mL saponin, we detected release of 90% of the platelet LDH into the washed supernatant ( Figure IIA in the online-only Data Supplement), which is a marker of plasma membrane permeabilization. However, at this concentration, α-granules remained intact as determined by the absence of release of soluble α-granule protein PF4 (platelet factor 4; Figure IIB in the online-only Data Supplement). Permeabilized GLUT3-KO platelets, with cytosolic proteins washed away and incubated with 13 C-1,6-glucose, displayed an ≈2.5-fold decrease in 13 C-lactic acid production ( Figure 1E ), suggesting that α-granule glycolysis is regulated in part via GLUT3-mediated glucose uptake.
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Glucose Metabolism in GLUT3-KO Megakaryocytes Was Unchanged
We then investigated whether metabolic alterations in platelets arise from dysfunctional megakaryocyte metabolism. Megakaryocytes derived from GLUT3-KO mouse bone marrow demonstrate reduced GLUT3 protein content but normal GLUT1 content ( Figure IIIA in the online-only Data Supplement). This was associated with no changes in basal glycolysis, and unlike GLUT3-KO platelets, GLUT3-KO megakaryocytes displayed no impairment in glycolysis after administration of mitochondrial inhibitors ( Figure IIIB in the online-only Data Supplement). In contrast to platelets, -2-deoxy-D-glucose (2-DOG) uptake in platelets was monitored in the presence or absence of 1 U/mL thrombin (IIa), n=7. C, Platelet glycolysis rate, as measured by the extracellular acidification rate (ECAR) was determined using a Seahorse XF24 analyzer. Platelet glycolysis rates with or without 1 U/mL thrombin (IIa) were monitored under basal conditions and after treatment with the mitochondrial inhibitors: Oligomycin, ATP synthase inhibitor; carbonyl cyanide-4 (trifluoromethoxy)phenylhydrazone (FCCP), mitochondrial uncoupler; and rotenone, mitochondrial complex I inhibitor, n=5. D, Metabolomics analysis of glycolytic intermediates in nonstimulated freshly isolated platelets, quantified as area under the curve (AUC), were determined and normalized to platelet number, n=5. Glycogen analysis was determined fluorometrically by the enzymatic conversion of glycogen to glucose, n=6. E, 13 C-lactic acid production by saponin permeabilized platelets, after incubation with 13 C-glucose, n=10. Data are mean±SEM. *P<0.05, **P<0.01,***P<0.001; 2-way analysis of variance (ANOVA) followed by Tukey multiple comparison post hoc test (B and C); Student t test (D and E). GLUT3-KO indicates platelet-specific knockout of GLUT3.
GLUT3-KO megakaryocytes had normal glycogen content ( Figure IIIC in the online-only Data Supplement). Together these data suggest that the metabolic changes in GLUT3-deficient platelets do not arise from dysfunctional glucose metabolism in megakaryocytes.
GLUT3-KO Mice Exhibit Decreased Autoimmune Inflammatory Arthritis
Platelets play an essential role in disease progression of rheumatoid arthritis in a collagen-dependent manner through platelet-derived microparticles and release of IL-1. 23 To explore postactivation functions of GLUT3, we considered the possibility that GLUT3-mediated glucose uptake may be required for microparticle formation. GLUT3-deficient platelets demonstrated no changes in nonstimulated, collagen-or thrombin-induced microparticle formation (Figure 2A through 2C). However, when mice were subjected to a K/BxN model of autoimmune inflammatory arthritis, we observed a modest but significant and durable reduction in clinical index (P=0.008) and ankle thickness (P=0.0003; Figure 2D and 2E). GLUT3-KO platelets displayed no changes in IL1A or IL1B transcripts ( Figure 2F ); however, total platelet IL-1α protein was significantly reduced ( Figure 2G ). Furthermore, GLUT3-KO platelets demonstrated decreased thrombin-stimulated IL-1α release ( Figure 2H ), suggesting that the attenuated inflammatory response could be due in part to reduced IL-1α signaling.
GLUT3-Deficient Platelets Demonstrated Decreased Platelet Function
Platelet counts were unchanged in GLUT3-KO mice (Table) . When GLUT3-KO mice were subjected to collagen/epinephrine-induced pulmonary embolism, a significant increase in survival was observed ( Figure 3A ). In contrast, no changes in hemostasis were observed by tail-bleeding time ( Figure  IV in the online-only Data Supplement). Given the evidence for decreased postactivation functions of platelets in vivo, we next examined static adhesion. Platelets were incubated on fibrinogen or collagen and treated with or without thrombin. GLUT3-KO platelets exhibited significantly impaired platelet spreading on both matrixes ( Figure 3B and 3C). Clot retraction occurs after platelet activation and requires glucose metabolism. 15 Interestingly, blood from GLUT3-KO mice demonstrated reduced clot retraction ( Figure 3D and 3E).
Platelet Activation Is Reduced in GLUT3-KO Platelets
GLUT3-KO platelets displayed impaired aggregation in response to 0.6 μg/mL collagen ( Figure 4A) ; however, at maximal collagen concentrations (1 μg/mL), aggregation was normalized to control levels ( Figure 4B ). Similarly, in response to 0.02 U/mL thrombin, GLUT3-KO platelets exhibited decreased aggregation ( Figure 4C ), but at maximal concentrations of thrombin (0.5 U/mL), aggregation normalized to control levels ( Figure 4D ). Flow cytometric analysis of diluted whole blood was performed and integrin αIIbβ 3 activation (JONA binding) and α-granule release (CD62p surface binding) monitored. GLUT3-KO platelets did not display changes in baseline activation. However, after stimulation with submaximal doses of Par4 (protease-activated receptor 4) peptide, the thromboxane A 2 analog U46619, and convulxin, GLUT3-KO platelets exhibited reduced integrin αIIbβ 3 activation ( Figure 4E ) and CD62p surface translocation ( Figure 4F ). Importantly, thrombin-and adenosine diphosphate (ADP)-mediated Ca 2+ mobilization was not impaired in GLUT3-KO platelets ( Figure 4G ).
α-Granule Release Is Impaired in GLUT3-KO Platelets
To determine whether decreased CD62p surface translocation was because of decreased α-granule number, we evaluated platelet ultrastructure. Under basal conditions, electron micrographs exhibited no differences in α-granule, δ-granule, or mitochondrial number relative to controls ( Figure 5A and 5B). However, after stimulation with Par4 peptide, GLUT3-KO platelets displayed a significant accumulation of partially released α-granules ( Figure 5A and 5C), which resemble decondensing α-granules, 14 suggesting a degranulation defect. To determine whether these changes were accompanied by impaired α-granule cargo release, the releasate from PAR4 peptide-stimulated platelets was evaluated for the protein content of angiogenic factors. The majority of the angiogenesis proteins assayed were reduced in GLUT3-KO releasates ( Figure 5D ), although a subset of proteins was unchanged. In addition, ELISA quantification of releasate from thrombinstimulated GLUT3-KO platelets exhibited reduced levels of PF4 ( Figure 5E ), and this decrease was not attributable to decreased total PF4 content ( Figure 5E ). This decreased degranulation was specific to α-granules because after stimulation, no change in δ-granule release was observed as measured by CD63 surface translocation and ATP release ( Figure 5F and 5G). Together, these data indicate that GLUT3-KO platelets specifically exhibit decreased α-granule release.
GLUT3-Mediated Glucose Uptake and Glycogenolysis Facilitate α-Granule Fusion
Platelets lacking GLUT3 demonstrate decreased α-granule release. Metabolic characterization of GLUT3-KO platelets demonstrated that GLUT3 facilitates increased agonistmediated glucose uptake, which occurs once GLUT3 translocates to the plasma membrane. Because α-granule release occurs through both a rapid single exocytosis followed by slower compound exocytosis, we hypothesized that GLUT3 translocation to the plasma membrane by single exocytosis increases glucose uptake, which then promotes additional α-granule degranulation by increasing glucose-mediated energy generation that potentiates exocytosis. Human PAR1 (protease-activated receptor 1) agonist-mediated CD62p surface translocation requires ≈10 minutes 24 ; therefore, to test this hypothesis, we examined α-granule degranulation, measured by CD62p surface translocation, for ≤20 minutes after a maximal stimulatory dose of thrombin. Interestingly, GLUT3-KO platelets demonstrated equivalent α-granule release as controls for the first 5 minutes. However, after 10 minutes, GLUT3-KO platelets displayed decreased degranulation relative to controls ( Figure 6A ). Similar kinetics were observed in Pf4 release ( Figure 6B ). Platelets contain glycogen stores, which are used on stimulation; therefore, we examined the rate by which glycogen is consumed after stimulation and found that glycogen is completely depleted by 10 minutes poststimulation ( Figure 6C ). Furthermore, we found that in control platelets, the glycogen phosphorylase inhibitor CP-316819 ( Figure VA and VB in the online-only Data Supplement) decreased platelet activation during the first 10 minutes after thrombin administration ( Figure 6D ). Although treatment with the glycogen phosphorylase inhibitor CP-316819 delayed early rates of poststimulation platelet degranulation (0-10 minutes), degranulation rates eventually normalized to levels of platelets not treated with the glycogen phosphorylase inhibitor after 20 minutes ( Figure 6D ). In GLUT3-KO platelets, thrombin stimulated degranulation increased for 10 minutes but declined thereafter ( Figure 6E ). However, after treatment with CP-316819, GLUT3-KO platelets demonstrated dramatically reduced degranulation that was significantly lower than levels observed in GLUT3-KO platelets treated with thrombin alone (Figure 6E ). In humans, CP-316819 inhibited α-granule release similar to murine platelets ( Figure 6F ). Together, these data suggest that glycogen mobilization is required for rapid/early degranulation, and GLUT3-mediated glucose uptake mediates later stages of platelet degranulation. In the absence of glycogenolysis, glucose uptake may compensate for and eventually normalize degranulation, and when glycogenolysis and GLUT3-mediated glucose uptake are simultaneously decreased, degranulation is severely inhibited.
Discussion
These studies investigated the contribution of GLUT3-mediated metabolism to platelet function. Here we show that GLUT3 mediates ≈20% of basal glucose uptake in quiescent platelets, and we definitively demonstrate that GLUT3 is required for increased glucose uptake in response to platelet activation. Moreover, we demonstrate that GLUT3 is required for in vivo thrombosis, platelet activation, degranulation, and clot retraction. These studies provide novel insights into the role of glucose metabolism in the temporal regulation of platelet degranulation, which has in vivo functional consequences. RNASeq analysis of human and murine platelets and megakaryocytes indicate that GLUT1 and GLUT3 are the only glucose transporters present in platelets. [8] [9] [10] Therefore, our findings suggest that GLUT1 might be the major mediator of basal glucose uptake. Although basal glucose uptake was reduced in the GLUT3-KO platelets, basal glycolysis rates were unchanged. This might indicate an increase in glycogen consumption, a decrease in nonglycolysis-mediated metabolism, or a decrease in glucose oxidation into the mitochondria. Glycogen content was decreased 3-fold in the GLUT3-KO platelets, and polyol pathway metabolites were significantly reduced. Additionally, mitochondrial respirations were unchanged under basal conditions in the GLUT3-KO platelets, and Seahorse analysis indicated increased mitochondrial reserve capacity in these platelets ( Figure VI in the online-only Data Supplement). These findings support a conclusion that in the absence of GLUT3-mediated glucose uptake, glycolysis is maintained by GLUT1-mediated glucose uptake, as well as increased glycogen utilization, and decreased glucose flux through nonglycolytic pathways.
Approximately 85% of GLUT3 resides in α-granule membranes under nonstimulated conditions. This led us to consider the possibility that GLUT3 facilitates glucose uptake from the cytosol into α-granules for intragranular glycolysis. Proteomic analysis of α-granules, where GLUT3 was used as a specific marker of α-granules and proteomic analysis of platelet releasates, indicates that all proteins required for glycolysis are present in these organelles. [20] [21] [22] Moreover, we now show that subcellular fractions enriched for α-granules exhibited the greatest amount of hexokinase activity, and LDH activity was measureable as well. Interestingly, LDH activity was detected in other subcellular fractions, suggesting that α-granule-derived pyruvate could be converted to lactate by LDH in other subcellular compartments. It is important to note the limitations of platelet subcellular fractionation approaches as evidenced by presence of RANTES (regulated on activation, normal T-cell expressed and secreted) in multiple fractions, which could be consistent with breakage of some of the α-granules. Despite this, hexokinase was enriched in particulate fractions. We interpret these findings to indicate that in platelets, the majority of hexokinase is highly associated with (particulate) matter, consistent with it being tightly membrane bound. Earlier studies of digitoninpermeabilized platelets indicated that the pelleted intracellular organelles were enriched for glycolytic intermediary metabolites and glycolytic enzyme activity, consistent with compartmentalization of glycolysis. 25 Moreover, these studies revealed that only 10% of hexokinase activity was found in the cytosolic supernatant. 25, 26 Hexokinase is also associated with mitochondria. Our analysis of mitochondrial-enriched fractions revealed hexokinase protein, but we did not detect any hexokinase activity. It is possible that because hexokinase might be loosely associated with the mitochondrial membrane, any activity could have been lost. Importantly, in a GLUT3-enriched membrane fraction that was devoid of mitochondrial contamination, we detected significant hexokinase activity. Taken together, these data support the conclusion that in platelets, hexokinase is not exclusively a soluble enzyme but rather is tightly associated with particulate compartments, such as α-granules. Using 13 C-labeled glucose, saponin-permeabilized platelets produced readily detectable lactic acid, and deletion of GLUT3 significantly reduced lactate efflux, supporting the hypothesis that GLUT3 facilitates glucose uptake into α-granules where it can then be used for glycolysis. These permeabilization experiments do not differentiate α-granules from other intact intracellular organelles, and determination of glycolysis in isolated murine α-granules would clarify this issue. However, isolation of α-granules from murine platelets is technically challenging and could not be achieved. GLUT3 has been described by multiple groups to be specifically localized to α-granules.
12,21,27
The enrichment of GLUT3 in α-granules and our evidence of hexokinase enrichment in this compartment, but the presence of LDH in α-granules and cytosolic fractions, raises the possibility that cross talk may exist between α-granule glucose metabolism and cytosolic metabolism. We speculate that the localization of hexokinase on α-granule membranes could play an important role in the compartmentalization of this process between the cytosol and the α-granule after GLUT3-mediated α-granule glucose uptake occurs.
One potential consequence of a specific reduction in α-granule glycolysis could be a reduction in platelet ATP generation either in α-granules or in the cytosol. It was not technically feasible to monitor ATP production in saponin-permeabilized platelets, possibly because of the low quantity of ATP produced by glycolysis and high quantity of stored ATP in δ-granules. Thus, we were unable to directly determine the functional consequence of changes in intragranular glycolysis in α-granules. However in neurons, subcellular localization of glycolysis has been suggested to regulate cellular function. 28 ATP is an essential cofactor for degranulation because in permeabilized platelets devoid of cytosol, although degranulation can be initiated with the addition of calcium, ATP addition is an absolute requirement. 29 It is possible that intragranule glycolysis or compartmentalization of glycolytic ATP generation via α-granule GLUT3 could regulate platelet degranulation though the luminal production of ATP for the ATPase N-ethylmaleimide-sensitive factor, which is required for degranulation. In addition to N-ethylmaleimide-sensitive factor, other ATP-dependent proteins have been identified via α-granule proteomic surveys, 21 which may be essential for platelet granule mobilization or maintenance. Future studies will be required to further elucidate the specific role of α-granule-regulated glycolysis to platelet function.
RNASeq analysis of murine megakaryocytes indicates robust expression of both GLUT1 and GLUT3 transcripts. 9 While significant quantities of GLUT3 are present in platelets, the GLUT1 transcript is expressed at low levels. 8, 10 These data suggest that GLUT1 is present earlier in development and might be important for megakaryocyte glucose metabolism, whereas GLUT3 may be induced later and assumes greater importance in platelets. PF4 Cre deletes GLUT3 in the megakaryocyte. However, in contrast to GLUT3-KO platelets, bone marrow-derived megakaryocytes displayed no changes in basal or metabolic stress-induced glycolysis or glycogen content. Thus, GLUT3 is not a major contributor to glucose metabolism in megakaryocytes. Therefore, the platelet dysfunction observed likely reflects the consequence of impaired GLUT3-mediated metabolism after platelets enter the circulation.
Permeabilized platelets devoid of cytosol maintain the ability to release α-granules when Ca 2+ and ATP are provided. 30 Interestingly, in response to thrombin stimulation, GLUT3-KO platelets exhibited normal cytosolic Ca 2+ mobilization, although α-granule release was significantly impaired. These observations support a model in which signaling pathways that lead to platelet activation might be intact in GLUT3-deficient platelets and that impaired ATP production may contribute to the platelet degranulation defect observed. GLUT3-mediated glucose uptake occurs after translocation of GLUT3-containing α-granules to the plasma membrane. Therefore, the observation that GLUT3-KO platelets exhibited decreased α-granule degranulation was intriguing. We considered the possibility that decreased glycogen content in GLUT3-KO mice contributed to decreased degranulation. In the presence of an inhibitor of glycogen phosphorylase, GLUT3-KO platelets demonstrated an additional reduction in platelet degranulation. These observations reveal a role for GLUT3-mediated glucose uptake in the initial and late release of α-granules. We further explored the possibility that the initial release of α-granules increases GLUT3 translocation to an extent that is sufficient to increase glucose utilization to generate the energy required for completion of platelet degranulation. When we examined the temporal regulation of degranulation, GLUT3-KO platelets initially demonstrated normal degranulation in response to thrombin stimulation; however, beyond 10 minutes poststimulation, GLUT3-KO platelets failed to increase degranulation to a similar rate as controls. Additionally, a glycogen phosphorylase inhibitor decreased early degranulation in wild-type and GLUT3-deficient platelets. These data suggest that glycogenolysis, which correlates temporally with single exocytosis, fuels initial degranulation, while GLUT3-mediated glucose uptake is important for the later stages of degranulation, particularly after endogenous glycogen stores are depleted. Moreover, electron micrographs of PAR4 peptide-stimulated platelets revealed that 10 minutes poststimulation, an accumulation of α-granules undergoing exocytosis was evident, suggesting that early degranulation might be intact but later stages of exocytosis are impaired. We observed a greater number of decondensing α-granules in GLUT3-deficient platelets. Although these findings could indicate granules arrested in compound exocytosis, additional 3D reconstruction image analysis would be needed to rigorously prove this. Together, these relationships support a model in which, as platelets degranulate, surface exposure of GLUT3 increases glucose uptake that generates the energy required to potentiate exocytosis that sustains platelet activation. -activated receptor 4) peptide. α-Granules in the process of degranulation (decondensing) depicted by red arrows, scale bar is 2 μm. B, Organelle density under nonstimulated conditions were quantified and normalized per platelet, n=4. C, Quantification of α-granules in the process of degranulation (decondensing) in PAR4-stimulated platelets, n=4. D, Par4 peptide-stimulated platelet releasate was monitored using a targeted angiogenesis protein array and expressed as percent change relative to control, n=1. E, ELISA quantification of PF4 (platelet factor 4) in whole platelet lysates and releasate from platelets stimulated with thrombin (1 U/mL), n=9. F, The δ-granule marker CD63 binding (geometric mean fluorescence intensity [Geo. MFI]) was monitored in washed platelets treated with the indicated agonist, n=3. G, ATP release was monitored, n=6. Data are mean±SEM. *P<0.05 vs control same treatment; 2-way analysis of variance (ANOVA) followed by Tukey multiple comparison post hoc test (B, E, F, and G). Student t test (C).
Until now, the significance of increased glucose uptake that occurs after platelets are activated was unclear. Here we demonstrate that fusion of α-granules containing GLUT3 to the plasma membrane is responsible for postactivation glucose uptake and α-granule release. Not all α-granule proteins were reduced in releasates from GLUT3-KO platelets. This was interesting because α-granules are thought to be separated into subpopulations based on their content. 31 Currently, we do not know if loss of GLUT3 leads to a specific repression of α-granule subpopulations.
GLUT3 is required for clot retraction. Previous studies have demonstrated that extracellular glucose plays an important role in clot retraction. However, those studies used inhibitors that impair glucose uptake via all transporters. Here we demonstrate that although basal glucose uptake is maintained in GLUT3-deficient platelets, the 2-fold increase in glucose uptake after platelet activation that is mediated by GLUT3 is essential for clot retraction.
Activated, platelets generate microparticles, which contribute importantly to the pathogenesis of rheumatoid arthritis disease progression and other immune responses. 23, 32 Microparticle formation is bioenergetically unfavorable and in vitro is observed for many hours after agonist stimulation. 33, 34 Thus, we considered the possibility that glucose uptake and glycolysis might be the primary energy source that fuels microparticle generation and release. Contrary to our hypothesis, Figure 6 . Temporal regulation of α-granule degranulation. A, Washed platelets stimulated with or without thrombin 1 U/mL at T=0 were monitored for CD62p geometric mean fluorescence intensity (Geo. MFI) at the indicated time points and normalized to control, n=6. B, Relative Pf4 (platelet factor 4) release in 1 U/mL thrombin-stimulated platelets at T=0, n=9. C, Platelets stimulated with 1 U/mL thrombin at T=0 and then glycogen content were determined at the indicated time points, 10 total mice, n=3. Control (D) or platelet-specific knockout of GLUT3 (GLUT3-KO; E) platelets were pretreated with or without 50 μmol/L CP-316819 and then were stimulated with 1 U/ mL thrombin at T=0, and CD62p Geo. MFI was monitored at the indicated times, n=6. F, Human platelets pretreated with CP-316819, stimulated with 1U/mL thrombin at t=0, and monitored for CD62p Geo. MFI, n=4. Data are mean±SEM. *P<0.05, **P<0.01,***P<0.001, ****P<0.0001; 2-way analysis of variance (ANOVA) followed by Tukey multiple comparison post hoc test (A, B, D, E, and F) ; 1-way ANOVA followed by Tukey multiple comparison post hoc test (C). GLUT3 indicates glucose transporter 3.
microparticle formation was not impaired in GLUT3 deficient platelets. However, in a model of autoimmune inflammatory arthritis, which is dependent on microparticle formation and IL-1 release, GLUT3-KO mice displayed decreased disease progression. Total cellular IL-1α protein was reduced, along with agonist-mediated IL-1α release, despite normal Il1a and Il1b transcript levels. Unlike IL-1β, which is induced on activation, 35 the mechanism of IL-1α synthesis in platelets is incompletely understood. 36 Given that GLUT3-deficient megakaryocytes in culture maintain glucose metabolism, our observations suggest that decreased basal glucose metabolism leads to post-transcriptional regulation of IL-1α in the circulating platelets. In human umbilical vein endothelial cells, IL-1α protein is synthesized by free ribosomes anchored to the cytoskeleton in the cytosol. In platelets, IL-1α has been shown to be located in a punctate distribution; however, these studies did not localize IL-1α to α-granules. 36 Our targeted angiogenesis analysis of platelet releasates suggests that IL-1α may also be an α-granule cargo or at least is associated with α-granule release. Thus, it is plausible that the reduction in IL-1α content may contribute to decreased arthritis disease progression. Because deletion of GLUT3 in platelets decreases inflammatory arthritis disease progression and increased survival after in vivo pulmonary embolism, GLUT3 could be considered a therapeutic target, for conditions mediated via inflammatory mediators that are released from activated platelets.
In summary these studies have elucidated the role of GLUT3-mediated glycolysis and glycogenolysis in the temporal regulation of platelet degranulation, postactivation clot retraction, and the release of inflammatory mediators that modulate disease progression. They underscore the biological and potential therapeutic significance of subcellular localization of energy metabolism in a subset of prothrombotic and immune platelet functions.
